durapatite has been researched along with Bone Loss, Perimenopausal in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y; He, J; Kang, K; Li, Z; Sun, X; Wu, Y; Zhu, Y | 1 |
| Cheng, J; Li, X; Lin, X; Liu, M; Liu, Q; Pavlos, NJ; Tan, Z; Tickner, J; Wang, T; Xu, J; Zhao, J; Zhou, L | 1 |
| Alghamdi, HS; Cuijpers, VM; Jansen, JA; van den Beucken, JJ; Wolke, JG | 1 |
| Kurth, A | 1 |
| Castelo-Branco, C; Dávila Guardia, J | 1 |
| Aati, O; Bristow, SM; Gamble, GD; Horne, AM; Horne, L; House, ME; Mihov, B; Reid, IR; Stewart, A | 1 |
| Bristow, SM; Gamble, GD; Horne, AM; Reid, IR; Stewart, A | 1 |
| Kettenberger, U; Luginbuehl, V; Pioletti, DP; Procter, P | 1 |
| Endo, N; Ohkawa, Y; Tokunaga, K | 1 |
| Ito, M; Mihara, M; Miyabe, S; Nakano, T; Shiraishi, A; Umakoshi, Y | 1 |
| Fratzl, P; Klaushofer, K; Li, C; Paris, O; Paschalis, EP; Roschger, P; Siegel, S | 1 |
| Kamo, K; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Sasaki, H; Shimada, Y | 1 |
| Khodyrev, VN; Lobanova, GM; Vitilina, MM | 1 |
| Aldini, NN; Fini, M; Giardino, R; Giavaresi, G; Greggi, T; Martini, L; Parisini, P | 1 |
| KROKOWSKI, E | 1 |
| Albertazzi, P; Howarth, EM; Purdie, DW; Steel, SA | 1 |
| Weiss, J | 1 |
| Bisset, JP; Confort-Gouny, S; Cozzone, PJ; Mattéi, JP; Roux, H; Vion-Dury, J | 1 |
| Kin, Y | 1 |
| Amati, S; Biagini, G; De Benedittis, A; Fini, M; Gandolfi, MG; Giardino, R; Giavaresi, G; Guzzardella, GA; Krayewski, A; Mattioli Belmonte, M; Nicoli Aldini, N; Ravaglioli, A; Rocca, M; Zucchini, C | 1 |
| Casals, E; Castelo-Branco, C; Martínez de Osaba, MJ; Pons, F; Sanjuán, A; Vanrell, JA; Vicente, JJ | 1 |
| Castelo-Branco, C; Pons, F; Sanjuán, A; Vanrell, JA; Vicente, JJ | 1 |
| Michi, K; Ohno, K; Pan, J; Shirota, T | 1 |
| Belkoff, SM; Deramond, H; Jasper, LE; Mathis, JM | 1 |
| de Raadt, M; Duursma, SA; Haspels, AA; Raymakers, JA | 1 |
| Cherveniashki, S; Katsarova, M; Khadzhiev, A; Rachev, E | 1 |
1 review(s) available for durapatite and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Use of ossein-hydroxyapatite complex in the prevention of bone loss: a review.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases; Durapatite; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pregnancy | 2015 |
7 trial(s) available for durapatite and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcium; Calcium Carbonate; Calcium Citrate; Calcium Phosphates; Calcium, Dietary; Collagen Type I; Dietary Supplements; Durapatite; Female; Humans; Osteoporosis, Postmenopausal; Peptides; Phosphates; Postmenopause | 2014 |
Acute effects of calcium supplements on blood pressure and blood coagulation: secondary analysis of a randomised controlled trial in post-menopausal women.
Topics: Aged; Aged, 80 and over; Blood Coagulation; Blood Coagulation Disorders; Blood Pressure; Bone Density Conservation Agents; Calcium Carbonate; Calcium Citrate; Calcium, Dietary; Cohort Studies; Dietary Supplements; Double-Blind Method; Durapatite; Elder Nutritional Physiological Phenomena; Female; Humans; Hypertension; Middle Aged; New Zealand; Osteoporosis, Postmenopausal; Patient Dropouts; Risk | 2015 |
[Clinical study of calcium-containing bioactive food additive in postmenopausal osteoporosis].
Topics: Calcium; Dietary Supplements; Durapatite; Dyssomnias; Fatigue; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pain; Treatment Outcome | 2002 |
Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Remodeling; Calcium Phosphates; Collagen Type I; Double-Blind Method; Durapatite; Female; Humans; Osteocalcin; Osteoporosis, Postmenopausal; Peptide Fragments; Prospective Studies; Reference Values | 2004 |
Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy.
Topics: Administration, Cutaneous; Adult; Biocompatible Materials; Bone Density; Chemotherapy, Adjuvant; Durapatite; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Treatment Outcome | 1999 |
Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial.
Topics: Aged; Bone Density; Calcium Carbonate; Durapatite; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 1999 |
[The results of a clinical trial of the preparation Ossopan].
Topics: Adult; Climacteric; Durapatite; Female; Humans; Hydroxyapatites; Middle Aged; Osteoporosis, Postmenopausal; Pregnancy; Pregnancy Complications; Tablets | 1990 |
18 other study(ies) available for durapatite and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Magnetic nanoparticle-infiltrated hydroxyapatite scaffolds accelerate osteoclast apoptosis by inhibiting autophagy-aggravated ER stress.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Durapatite; Female; Humans; Magnetite Nanoparticles; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Rats; Reactive Oxygen Species | 2022 |
Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways.
Topics: Animals; Anthocyanins; Bone Density Conservation Agents; Calcium Signaling; Disease Models, Animal; Dose-Response Relationship, Drug; Durapatite; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, Inbred C57BL; NF-kappa B; NF-KappaB Inhibitor alpha; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; Phosphorylation; Proteolysis; Proto-Oncogene Proteins c-fos; RANK Ligand; RAW 264.7 Cells | 2018 |
Calcium-phosphate-coated oral implants promote osseointegration in osteoporosis.
Topics: Animals; Bone Density; Bone Remodeling; Coated Materials, Biocompatible; Dental Etching; Dental Implants; Dental Materials; Dental Prosthesis Design; Disease Models, Animal; Durapatite; Female; Femur; Fluorescent Dyes; Humans; Osseointegration; Osteoblasts; Osteoclasts; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar; Stress, Mechanical; Surface Properties; Time Factors; Titanium; X-Ray Microtomography | 2013 |
[Impacts on bone mineral density].
Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Diphosphonates; Durapatite; Extracellular Space; Female; Humans; Organometallic Compounds; Osteoporosis, Postmenopausal; Thiophenes | 2014 |
In vitro and in vivo investigation of bisphosphonate-loaded hydroxyapatite particles for peri-implant bone augmentation.
Topics: Animals; Bone Substitutes; Diphosphonates; Disease Models, Animal; Durapatite; Female; Femur; Humans; Imidazoles; Mice; Osteoporosis, Postmenopausal; Rats; Rats, Wistar; RAW 264.7 Cells; Zoledronic Acid | 2017 |
Intermittent administration of human parathyroid hormone (1-34) increases new bone formation on the interface of hydroxyapatitecoated titanium rods implanted into ovariectomized rat femora.
Topics: Animals; Arthroplasty, Replacement, Hip; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Regeneration; Coated Materials, Biocompatible; Disease Models, Animal; Durapatite; Female; Femur; Humans; Osteoporosis, Postmenopausal; Ovariectomy; Parathyroid Hormone; Rats; Rats, Sprague-Dawley | 2008 |
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Durapatite; Etidronic Acid; Female; Femur; Humans; Hydroxycholecalciferols; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar; Risedronic Acid; Stress, Mechanical; Treatment Outcome; Weight-Bearing; X-Ray Diffraction; X-Ray Microtomography | 2009 |
Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment.
Topics: Biopsy; Bone and Bones; Bone Density Conservation Agents; Durapatite; Female; Humans; Ilium; Organometallic Compounds; Osteoporosis, Postmenopausal; Scattering, Small Angle; Spectrometry, X-Ray Emission; Strontium; Thiophenes; X-Ray Diffraction | 2010 |
Intermittent weekly administration of human parathyroid hormone (1-34) improves bone-hydroxyapatite block bonding in ovariectomized rats.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Bone Substitutes; Durapatite; Female; Humans; Knee; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Teriparatide; Tibia | 2010 |
Biological assessment of the bone-screw interface after insertion of uncoated and hydroxyapatite-coated pedicular screws in the osteopenic sheep.
Topics: Animals; Biocompatible Materials; Bone Diseases, Metabolic; Bone Screws; Coated Materials, Biocompatible; Disease Models, Animal; Durapatite; Female; Hardness Tests; Humans; Lumbar Vertebrae; Materials Testing; Osseointegration; Osteoporosis, Postmenopausal; Ovariectomy; Sheep; Stainless Steel; Wound Healing | 2003 |
[INTERPRETATION AND MISINTERPRETATION OF POSTMENOPAUSAL OSTEOPOROSIS].
Topics: Bone and Bones; Calcium; Durapatite; Female; Hormones; Humans; Menopause; Metabolism; Osteoporosis; Osteoporosis, Postmenopausal; Radiography | 1964 |
[Osteoporosis-induced fractures: what therapeutic possibilities are available?].
Topics: Age Factors; Aged; Bone Cements; Durapatite; Female; Fractures, Spontaneous; Humans; Middle Aged; Osseointegration; Osteoporosis, Postmenopausal; Polymethyl Methacrylate; Spinal Fractures; Spine; Treatment Outcome | 2006 |
Phosphorus-31 in vivo magnetic resonance spectroscopy of bone fails to diagnose osteoporosis.
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Durapatite; Female; Humans; Magnetic Resonance Spectroscopy; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus Isotopes; Wrist | 1995 |
[Histological observations of hydroxyapatite thermal decomposition product injected into the femur of ovariectomized rats].
Topics: Animals; Biocompatible Materials; Bone Cements; Bone Development; Calcium Phosphates; Disease Models, Animal; Durapatite; Female; Femur; Hot Temperature; Humans; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar | 1994 |
Biomaterials for orthopedic surgery in osteoporotic bone: a comparative study in osteopenic rats.
Topics: Animals; Biocompatible Materials; Bone Diseases, Metabolic; Durapatite; Electron Spin Resonance Spectroscopy; Female; Femur; Humans; Microscopy, Electron, Scanning; Osseointegration; Osteoporosis, Postmenopausal; Ovariectomy; Prostheses and Implants; Rats; Rats, Sprague-Dawley; Titanium | 1997 |
Effect of ovariectomy on bone remodeling adjacent to hydroxyapatite-coated implants in the tibia of mature rats.
Topics: Animals; Bone Density; Bone Remodeling; Coated Materials, Biocompatible; Dental Implantation, Endosseous; Disease Models, Animal; Durapatite; Estrogens; Female; Humans; Osseointegration; Osteoporosis, Postmenopausal; Ovariectomy; Ovary; Prostheses and Implants; Rats; Rats, Wistar; Statistics, Nonparametric; Tibia | 2000 |
An ex vivo biomechanical evaluation of a hydroxyapatite cement for use with vertebroplasty.
Topics: Aged; Aged, 80 and over; Bone Cements; Bone Density; Cadaver; Compressive Strength; Durapatite; Female; Fracture Fixation, Internal; Humans; Lumbar Vertebrae; Materials Testing; Osteoporosis, Postmenopausal; Pliability; Polymethyl Methacrylate; Radiography; Spinal Fractures; Thoracic Vertebrae | 2001 |
Is 1 mg of estradiol valerate or 0.625 mg of conjugated estrogens sufficient for all women to prevent menopausal bone loss?
Topics: Adult; Bone Density; Durapatite; Estradiol; Estrogens, Conjugated (USP); Female; Humans; Hydroxyapatites; Middle Aged; Osteoporosis, Postmenopausal | 1992 |